Sp1057

NOVEL DIAGNOSTIC AND MANAGEMENT TOOLS FOR EOE - STATE OF THE ART

Date
May 21, 2024

Presenter

Speaker Image for Ikuo Hirano

Tracks

Related Products

Thumbnail for FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…
Thumbnail for PRESENTATION OF ESOPHAGEAL, GASTRIC & DUODENAL DISORDERS (EGD) SECTION RESEARCH MENTOR AWARD: IKUO HIRANO, MD
Thumbnail for FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
Thumbnail for EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…